It is a bit fishy to me. There are no news, and knowing that the losses will be reported, investors conference is being scheduled before the ASCO abstracts, it would be more "productive" to have an investors conference past ASCO announcements unless you have something not to pleasant to say upfront . It is too early to report COMET trials results. Renal cancer is still a rare disease not a big market. There is basically nothing solid at the moment to justify the price going up. Could be a play behind the curtains
A copy and paste from the NCI site:
It is estimated that 64,770 men and women (40,250 men and 24,520 women) will be diagnosed with and 13,570 men and women will die of cancer of the kidney and renal pelvis in 2012.